Corvus (CRVS) Q2 Loss Beats Estimates

Corvus Pharmaceuticals (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies, released its earnings results for Q2 2025 on August 7, 2025. The most notable update was a smaller net loss per share of $(0.10) (GAAP), outperforming the analyst consensus estimate of $(0.13). As the company has not yet commercialized any therapies. The period saw a significant expansion in research and development spending. and an improved cash position, thanks to warrant exercises. Overall, the quarter highlighted progress in advancing the clinical pipeline and extended financial runway, balanced against growing operating expenses and sustained net losses. Source: Analyst estimates for the quarter provided by FactSet. Corvus Pharmaceuticals is developing targeted therapies in immunology and oncology, with a primary focus on soquelitinib, an oral small molecule inhibitor targeting ITK (interleukin-2 inducible T cell kinase). Its leading clinical programs are in atopic dermatitis (an inflammatory skin disease) and peripheral T cell lymphoma (a rare and aggressive blood cancer). The company aims to advance these candidates through various stages of clinical development to achieve regulatory approvals.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool